STOCK TITAN

Orchard Therapeutics plc - $ORTX STOCK NEWS

Welcome to our dedicated page for Orchard Therapeutics plc news (Ticker: $ORTX), a resource for investors and traders seeking the latest updates and insights on Orchard Therapeutics plc stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Orchard Therapeutics plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Orchard Therapeutics plc's position in the market.

Rhea-AI Summary
Orchard Therapeutics (Nasdaq: ORTX) reported $5.6 million in quarterly Libmeldy net revenue and $12.7 million year-to-date. The company announced a planned acquisition by Kyowa Kirin valued at up to $477.6 million, with the U.S. FDA accepting the Biologics License Application for OTL-200 in MLD under Priority Review. Orchard Therapeutics highlighted ten active newborn screening studies globally and presented eight sessions at ESGCT. The company's CEO expressed optimism for the future and provided an overview of the financial results for the quarter ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
-
Rhea-AI Summary
Orchard Therapeutics announces positive clinical outcomes for gene therapy treatment of MPS-IH
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
none
-
Rhea-AI Summary
Orchard Therapeutics to present eight presentations at ESGCT Congress showcasing the potential of their HSC gene therapy platform. Data from a study of OTL-203 in MPS-IH shows positive outcomes. CTO Nicoletta Loggia to discuss manufacturing strategies for gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
Rhea-AI Summary
Lifshitz Law PLLC announces investigations of SLGC, ORTX, SP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Kyowa Kirin to acquire Orchard Therapeutics for $16.00 per ADS in cash, representing a total maximum equity value of approximately $477.6 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
95.95%
Tags
-
Rhea-AI Summary
Orchard Therapeutics announces FDA acceptance of BLA for OTL-200 in MLD with PDUFA date set for March 18, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.61%
Tags
none
Rhea-AI Summary
Orchard Therapeutics announces long-term results of gene therapy for metachromatic leukodystrophy, showing significant improvement in motor function and cognitive preservation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
-
Rhea-AI Summary
Orchard Therapeutics (Nasdaq: ORTX) reported $6.6M in Q2’23 Libmeldy net sales, securing $34.0M of additional capital from second closing of strategic financing. The company identified four MLD patients from ~150,000 newborns screened, suggesting higher incidence than previously estimated. Six presentations at ASGCT showcased HSC gene therapy's potential. The BLA submission for OTL-200 to the FDA is completed, and the company expects acceptance in Q3’23.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
none
Rhea-AI Summary
Orchard Therapeutics will host a conference call and live webcast on August 3, 2023, to review business updates and its second quarter 2023 financial results. The webcast will be available on the company's website and a replay will be archived.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.74%
Tags
conferences earnings
Orchard Therapeutics plc

Nasdaq:ORTX

ORTX Rankings

ORTX Stock Data

380.11M
117.51M
12.21%
103.6%
0.14%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United Kingdom
108 Cannon Street

About ORTX

orchard therapeutics is dedicated to bringing transformative gene therapies to children with life-threatening orphan diseases. we work in partnership with the world’s most prestigious research centres to harness the life-giving potential of gene therapy. orchard’s leadership team and collaborators have more than a decade of experience in the development, manufacturing and commercialization of advanced therapies for orphan diseases. our mission is to provide the ideal environment and expertise to translate promising pre-clinical and early clinical results into commercially approved medicines available to patients around the world.